BCL2 and acute myeloid leukemia: Venetoclax, an oral BCL-2 inhibitor, has been approved for the treatment of older AML patients ineligible for intensive chemotherapy by the United States Food and Drug Administration (FDA) in combination with low-dose cytarabine (LDAC) or hypomethylating agents (HMA) such as azacitidine and decitabine.